{"id":"placebo-sinemet","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1201236","moleculeType":"Small molecule","molecularWeight":"226.23"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Carbidopa inhibits the conversion of levodopa to dopamine outside the brain, allowing more levodopa to cross the blood-brain barrier and increasing dopamine levels in the brain. This helps to alleviate symptoms of Parkinson's disease, such as tremors and stiffness.","oneSentence":"Sinemet is a combination of carbidopa and levodopa, which work together to increase dopamine levels in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:24.801Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Parkinson's disease with fluctuations"}]},"trialDetails":[{"nctId":"NCT04469959","phase":"PHASE2","title":"Dopaminergic Dysfunction in Late-Life Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-02-15","conditions":"Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant","enrollment":100},{"nctId":"NCT06075771","phase":"PHASE4","title":"Dopaminergic Therapy for Anhedonia - 2","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-11-21","conditions":"Anhedonia, Depression","enrollment":70},{"nctId":"NCT05708274","phase":"PHASE1","title":"Pharmacological Agents for Chronic Spinal Cord Injury (SCI)","status":"COMPLETED","sponsor":"Bronx VA Medical Center","startDate":"2023-01-20","conditions":"Spinal Cord Injuries","enrollment":25},{"nctId":"NCT06219915","phase":"PHASE1, PHASE2","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2024-03-15","conditions":"Parkinsonian Signs in Older Persons","enrollment":13},{"nctId":"NCT04006210","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations","status":"ACTIVE_NOT_RECRUITING","sponsor":"NeuroDerm Ltd.","startDate":"2019-09-30","conditions":"Parkinson's Disease","enrollment":381},{"nctId":"NCT05132660","phase":"EARLY_PHASE1","title":"Treating Early Stage Diabetic Retinopathy","status":"ENROLLING_BY_INVITATION","sponsor":"VA Office of Research and Development","startDate":"2022-07-01","conditions":"Diabetic Retinopathy","enrollment":244},{"nctId":"NCT06596876","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-11-06","conditions":"Parkinson's Disease","enrollment":450},{"nctId":"NCT05369533","phase":"PHASE1, PHASE2","title":"Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-08-01","conditions":"Stroke","enrollment":25},{"nctId":"NCT05285683","phase":"PHASE2","title":"The Role of Brain Dopamine in Chronic Pain","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2024-01-31","conditions":"Chronic Pain","enrollment":10},{"nctId":"NCT04723147","phase":"PHASE4","title":"DTA (Dopaminergic Therapy for Anhedonia) Study","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-01-29","conditions":"Depression, Anhedonia","enrollment":19},{"nctId":"NCT05463367","phase":"PHASE2","title":"Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2021-01-01","conditions":"Opioid Use, Opioid Dependence, Opioid-use Disorder","enrollment":60},{"nctId":"NCT03735901","phase":"PHASE3","title":"Enhancement of Stroke Rehabilitation With Levodopa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2019-06-14","conditions":"Acute Stroke, Stroke Rehabilitation","enrollment":610},{"nctId":"NCT01725802","phase":"PHASE1","title":"A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2012-12-16","conditions":"Parkinson's Disease","enrollment":8},{"nctId":"NCT00456794","phase":"PHASE2","title":"12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2002-03","conditions":"Parkinson's Disease","enrollment":325},{"nctId":"NCT00199420","phase":"PHASE3","title":"A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2004-07","conditions":"Parkinson's Disease","enrollment":580},{"nctId":"NCT00456586","phase":"PHASE2","title":"12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2002-04","conditions":"Parkinson's Disease","enrollment":180},{"nctId":"NCT03451500","phase":"PHASE2","title":"Carbidopa-Levodopa in Dry AMD With Geographic Atrophy","status":"TERMINATED","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","startDate":"2018-07-01","conditions":"Age Related Macular Degeneration","enrollment":7},{"nctId":"NCT00199407","phase":"PHASE3","title":"A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2004-06","conditions":"Parkinson's Disease","enrollment":230},{"nctId":"NCT05087914","phase":"PHASE2","title":"Novel Non-opioid Post-surgical Pain Treatment in Females","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2021-11-01","conditions":"Acute Pain, Bunionectomy, Toe Fusion","enrollment":""},{"nctId":"NCT03111485","phase":"PHASE4","title":"Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2017-05-24","conditions":"Parkinson's Disease, Obstructive Sleep Apnea","enrollment":36},{"nctId":"NCT01486628","phase":"PHASE1","title":"Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2012-04-30","conditions":"Parkinson's Disease","enrollment":36},{"nctId":"NCT01883505","phase":"PHASE2","title":"A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2014-01-06","conditions":"Parkinson's Disease","enrollment":30},{"nctId":"NCT04052776","phase":"PHASE1","title":"Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2020-09-11","conditions":"Spinal Cord Injuries, Drug Effect","enrollment":3},{"nctId":"NCT03761030","phase":"PHASE4","title":"L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2019-01-09","conditions":"Major Depressive Disorder, Dysthymia, Depression","enrollment":51},{"nctId":"NCT04493320","phase":"PHASE4","title":"1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2021-02-10","conditions":"Depression, Cognitive Impairment, Gait Impairment","enrollment":5},{"nctId":"NCT00590122","phase":"PHASE4","title":"Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2006-10","conditions":"Parkinson's Disease","enrollment":20},{"nctId":"NCT04742348","phase":"PHASE4","title":"Research on Translational Outcomes of Alcohol (Project RETRO)","status":"WITHDRAWN","sponsor":"University of Washington","startDate":"2023-02","conditions":"Alcohol Drinking","enrollment":""},{"nctId":"NCT03670953","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2018-11-06","conditions":"Parkinson's Disease (Disorder)","enrollment":630},{"nctId":"NCT05083260","phase":"PHASE1, PHASE2","title":"NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa","status":"COMPLETED","sponsor":"BioVie Inc.","startDate":"2022-01-04","conditions":"Parkinson Disease","enrollment":46},{"nctId":"NCT04650217","phase":"PHASE4","title":"Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2021-10-07","conditions":"Depressive Disorder","enrollment":1},{"nctId":"NCT04380142","phase":"PHASE3","title":"Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-10-19","conditions":"Parkinson's Disease (PD)","enrollment":174},{"nctId":"NCT04000919","phase":"PHASE2, PHASE3","title":"Effects of 5HTP and LDOPA on CNS Excitability After SCI","status":"SUSPENDED","sponsor":"Jessica M D'Amico","startDate":"2019-06-19","conditions":"Spinal Cord Injuries","enrollment":30},{"nctId":"NCT02513485","phase":"PHASE4","title":"Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-10-09","conditions":"Depression","enrollment":57},{"nctId":"NCT03929068","phase":"PHASE1","title":"Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-05-13","conditions":"Amyotrophic Lateral Sclerosis, Motor Neuron Disease","enrollment":15},{"nctId":"NCT02346630","phase":"PHASE4","title":"Combining Robotic-Assisted Therapy and Pharmacotherapy in Post-Stroke Rehabilitation","status":"WITHDRAWN","sponsor":"Ross D. Zafonte, MD","startDate":"2015-03","conditions":"Stroke","enrollment":""},{"nctId":"NCT05128175","phase":"PHASE1","title":"Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions","status":"UNKNOWN","sponsor":"Shanghai WD Pharmaceutical Co., Ltd.","startDate":"2021-10-29","conditions":"Parkinson Disease","enrollment":15},{"nctId":"NCT05036473","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease","status":"UNKNOWN","sponsor":"Shanghai WD Pharmaceutical Co., Ltd.","startDate":"2021-10-12","conditions":"Parkinson Disease","enrollment":40},{"nctId":"NCT01951105","phase":"PHASE4","title":"Effect of L-dopa In Subacute Back Pain Population","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2015-02-24","conditions":"Sub-acute Back Pain","enrollment":72},{"nctId":"NCT01171313","phase":"PHASE2","title":"A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2010-07","conditions":"Parkinson's Disease","enrollment":35},{"nctId":"NCT01281475","phase":"PHASE2, PHASE3","title":"A Trial of Levodopa in Angelman Syndrome","status":"COMPLETED","sponsor":"Wen-Hann Tan","startDate":"2011-01","conditions":"Angelman Syndrome","enrollment":67},{"nctId":"NCT04082715","phase":"PHASE2","title":"Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity","status":"WITHDRAWN","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2019-10","conditions":"Chronic Back Pain","enrollment":""},{"nctId":"NCT02782481","phase":"PHASE3","title":"A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations","status":"WITHDRAWN","sponsor":"NeuroDerm Ltd.","startDate":"2016-08","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT02386475","phase":"PHASE4","title":"Effect of Serotonin and Levodopa in Ischemic Stroke","status":"COMPLETED","sponsor":"Hospital de Granollers","startDate":"2015-01","conditions":"Stroke","enrollment":39},{"nctId":"NCT00880620","phase":"PHASE3","title":"A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2009-04","conditions":"Parkinson's Disease","enrollment":381},{"nctId":"NCT00279825","phase":"PHASE2","title":"Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2006-01","conditions":"Idiopathic Parkinson's Disease","enrollment":16},{"nctId":"NCT00253084","phase":"PHASE2","title":"Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2005-11","conditions":"Parkinson's Disease","enrollment":12},{"nctId":"NCT02605434","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients","status":"UNKNOWN","sponsor":"Intec Pharma Ltd.","startDate":"2016-03","conditions":"Parkinson's Disease","enrollment":420},{"nctId":"NCT03665454","phase":"PHASE1","title":"PF 06412562 in Subjects With Advanced Stage Parkinson's Disease","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2018-09-24","conditions":"Parkinson Disease","enrollment":8},{"nctId":"NCT02873351","phase":"PHASE2","title":"A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration","status":"WITHDRAWN","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","startDate":"2019-09","conditions":"Age-related Macular Degeneration","enrollment":""},{"nctId":"NCT02812147","phase":"PHASE2","title":"Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease","status":"UNKNOWN","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2016-05","conditions":"Parkinson Disease","enrollment":20},{"nctId":"NCT01468012","phase":"PHASE2, PHASE3","title":"Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2014-07","conditions":"Cocaine Dependence","enrollment":23},{"nctId":"NCT00713583","phase":"PHASE2","title":"Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2008-01","conditions":"Cocaine Dependence","enrollment":85},{"nctId":"NCT02080819","phase":"PHASE2","title":"Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2014-02","conditions":"Cocaine Dependence","enrollment":131},{"nctId":"NCT01393457","phase":"PHASE2","title":"Cognitive Remediation for Cocaine Dependence","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2011-06","conditions":"Cocaine Dependence","enrollment":119},{"nctId":"NCT00715520","phase":"NA","title":"Neurobiological Principles Applied to the Rehabilitation of Stroke Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2007-04","conditions":"Stroke","enrollment":33},{"nctId":"NCT01617135","phase":"PHASE2","title":"Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and \"Off\" Episodes","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2012-05","conditions":"Idiopathic Parkinson's Disease","enrollment":25},{"nctId":"NCT00218023","phase":"PHASE2","title":"Medications for Stopping Cocaine Dependence and Preventing Relapse","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2006-03","conditions":"Cocaine Abuse, Cocaine-Related Disorders","enrollment":101},{"nctId":"NCT03103399","phase":"PHASE2","title":"Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With \"Wearingoff\" Phenomenon","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2006-09-26","conditions":"Parkinson Disease","enrollment":254},{"nctId":"NCT03091868","phase":"PHASE1","title":"Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-11-03","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT00223691","phase":"PHASE1","title":"Treatment of Orthostatic Hypotension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2002-03","conditions":"Autonomic Failure, Orthostatic Hypotension","enrollment":389},{"nctId":"NCT02170376","phase":"PHASE1","title":"The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2011-09","conditions":"Parkinson's Disease (PD)","enrollment":80},{"nctId":"NCT02834507","phase":"PHASE2","title":"Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2005-03","conditions":"Parkinson's Disease (PD)","enrollment":19},{"nctId":"NCT01190813","phase":"PHASE3","title":"Levodopa for the Treatment of Residual Amblyopia","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2010-09","conditions":"Amblyopia","enrollment":139},{"nctId":"NCT02774564","phase":"PHASE1","title":"Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2005-09","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT02763839","phase":"PHASE1","title":"Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2001-04","conditions":"Parkinson's Disease","enrollment":19},{"nctId":"NCT01568047","phase":"PHASE2","title":"Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2010-02","conditions":"Parkinson's Disease","enrollment":40},{"nctId":"NCT02169414","phase":"PHASE1","title":"Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2010-02","conditions":"Parkinson's Disease (PD)","enrollment":74},{"nctId":"NCT01533116","phase":"PHASE1","title":"Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2009-03","conditions":"Parkinson Disease","enrollment":52},{"nctId":"NCT01484184","phase":"PHASE1, PHASE2","title":"Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury","status":"COMPLETED","sponsor":"Nordic Life Science Pipeline Inc.","startDate":"2013-07","conditions":"Spinal Cord Injury","enrollment":50},{"nctId":"NCT01519284","phase":"PHASE1","title":"Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2009-11","conditions":"Parkinson Disease","enrollment":82},{"nctId":"NCT02169479","phase":"PHASE1","title":"Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2008-09","conditions":"Parkinson's Disease (PD)","enrollment":16},{"nctId":"NCT01840423","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2013-05","conditions":"Healthy","enrollment":101},{"nctId":"NCT02169453","phase":"PHASE1","title":"Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2008-10","conditions":"Parkinson's Disease (PD)","enrollment":12},{"nctId":"NCT00357994","phase":"PHASE3","title":"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-01","conditions":"Advanced Parkinson's Disease","enrollment":36},{"nctId":"NCT00660387","phase":"PHASE3","title":"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-12","conditions":"Advanced Parkinson's Disease","enrollment":35},{"nctId":"NCT01568034","phase":"PHASE2","title":"A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2009-04","conditions":"Parkinson's Disease","enrollment":10},{"nctId":"NCT02116790","phase":"PHASE2","title":"Efficacy of Co-administration of an NSAID With a Dopamine Agonist In Healthy Subjects","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2014-05","conditions":"Acute Pain","enrollment":""},{"nctId":"NCT01688089","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2012-09","conditions":"Healthy","enrollment":67},{"nctId":"NCT01429077","phase":"PHASE2, PHASE3","title":"Augmenting Language Therapy for Aphasia: Levodopa","status":"COMPLETED","sponsor":"Shirley Ryan AbilityLab","startDate":"2007-10","conditions":"Nonfluent Aphasia, Stroke","enrollment":36},{"nctId":"NCT01026428","phase":"PHASE1, PHASE2","title":"A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2009-09","conditions":"Idiopathic Parkinson's Disease","enrollment":24},{"nctId":"NCT01351168","phase":"PHASE2","title":"Use of Zolpidem in Parkinson's Disease","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT01229332","phase":"PHASE1, PHASE2","title":"A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2011-01","conditions":"Parkinson's Disease","enrollment":24},{"nctId":"NCT01296464","phase":"PHASE2","title":"Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2011-02","conditions":"Parkinson's Disease","enrollment":27},{"nctId":"NCT01361373","phase":"PHASE4","title":"Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study","status":"UNKNOWN","sponsor":"Shaare Zedek Medical Center","startDate":"2010-05","conditions":"Dystonic Cerebral Palsy","enrollment":50},{"nctId":"NCT00642356","phase":"PHASE4","title":"Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off","status":"TERMINATED","sponsor":"Novartis","startDate":"2008-03","conditions":"Parkinson's Disease","enrollment":14},{"nctId":"NCT01103011","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2010-04","conditions":"Parkinson's Disease","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":41,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo- Sinemet","genericName":"Placebo- Sinemet","companyName":"Intec Pharma Ltd.","companyId":"intec-pharma-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sinemet is a combination of carbidopa and levodopa, which work together to increase dopamine levels in the brain. Used for Parkinson's disease, Parkinson's disease with fluctuations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}